Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct 9:11:573479.
doi: 10.3389/fendo.2020.573479. eCollection 2020.

Impact of Psychotropic Medication Effects on Obesity and the Metabolic Syndrome in People With Serious Mental Illness

Victor Mazereel  1   2 , Johan Detraux  2 , Davy Vancampfort  2   3 , Ruud van Winkel  1   2 , Marc De Hert  1   2   4
Affiliations
Review

Impact of Psychotropic Medication Effects on Obesity and the Metabolic Syndrome in People With Serious Mental Illness

Victor Mazereel et al. Front Endocrinol (Lausanne). .

Abstract

People with serious mental illness (SMI), including schizophrenia, bipolar disorder, and major depressive disorder, have a higher mortality rate and shortened life expectancy. This is mainly attributable to physical diseases, particularly cardiovascular diseases (CVDs). Important risk factors for CVDs are obesity and other metabolic abnormalities, which are especially prevalent in people with SMI. Several factors contribute to this increased risk, including unhealthy lifestyles. Psychotropic medication independently further increases this risk. In this review we want to examine the relationship between obesity and other components of the metabolic syndrome and psychotropic medication in people with SMI.

Keywords: antidepressant; antipsychotic; metabolic syndrome; mood stabilizer; obesity; serious mental illness.

PubMed Disclaimer

References

    1. Correll CU, Detraux J, De Lepeleire J, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry (2015) 14(2):119–36. 10.1002/wps.20204 - DOI - PMC - PubMed
    1. Hayes JF, Miles J, Walters K, King M, Osborn DPJ. A systematic review and meta-analysis of premature mortality in bipolar affective disorder. Acta Psychiatr Scand (2015) 131(6):417–25. 10.1111/acps.12408 - DOI - PMC - PubMed
    1. Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease burden implications a systematic review and meta-analysis. JAMA Psychiatry (2015) 72(4):334–41. 10.1001/jamapsychiatry.2014.2502 - DOI - PMC - PubMed
    1. De Hert M, Detraux J. The urgent need for optimal monitoring of metabolic adverse effects in children and youngsters who take on-label or off-label antipsychotic medication. JAMA Psychiatry (2018) 75(8):771–2. 10.1001/jamapsychiatry.2018.1080 - DOI - PubMed
    1. Maj M, van Os J, De Hert M, Gaebel W, Galderisi S, Green MF, et al. The clinical characterization of the patient with primary psychosis. World Psychiatry (2020). - PMC - PubMed